These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 18312556)

  • 1. A phase II clinical trial of vinorelbine in dogs with cutaneous mast cell tumors.
    Grant IA; Rodriguez CO; Kent MS; Sfilgoi G; Gordon I; Davis G; Lord L; London CA
    J Vet Intern Med; 2008; 22(2):388-93. PubMed ID: 18312556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chlorambucil and prednisolone chemotherapy for dogs with inoperable mast cell tumours: 21 cases.
    Taylor F; Gear R; Hoather T; Dobson J
    J Small Anim Pract; 2009 Jun; 50(6):284-9. PubMed ID: 19527421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vinblastine and prednisolone as adjunctive therapy for canine cutaneous mast cell tumors.
    Davies DR; Wyatt KM; Jardine JE; Robertson ID; Irwin PJ
    J Am Anim Hosp Assoc; 2004; 40(2):124-30. PubMed ID: 15007048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of canine mast cell tumors with CCNU (lomustine).
    Rassnick KM; Moore AS; Williams LE; London CA; Kintzer PP; Engler SJ; Cotter SM
    J Vet Intern Med; 1999; 13(6):601-5. PubMed ID: 10587263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse haematological effects of vinblastine, prednisolone and cimetidine treatment: a retrospective study in fourteen dogs with mast cell tumours.
    Trumel C; Bourgès-Abella N; Touron C; Lanore D; Geffré A; Diquelou A; Guelfi JF; Braun JP
    J Vet Med A Physiol Pathol Clin Med; 2005 Aug; 52(6):275-9. PubMed ID: 16050908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prednisone and vinblastine chemotherapy for canine mast cell tumor--41 cases (1992-1997).
    Thamm DH; Mauldin EA; Vail DM
    J Vet Intern Med; 1999; 13(5):491-7. PubMed ID: 10499735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-escalating vinblastine for the treatment of canine mast cell tumour.
    Vickery KR; Wilson H; Vail DM; Thamm DH
    Vet Comp Oncol; 2008 Jun; 6(2):111-9. PubMed ID: 19178670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study to evaluate the toxicity and efficacy of alternating CCNU and high-dose vinblastine and prednisone (CVP) for treatment of dogs with high-grade, metastatic or nonresectable mast cell tumours.
    Rassnick KM; Bailey DB; Russell DS; Flory AB; Kiselow MA; Intile JL; Malone EK; Balkman CE; Barnard SM
    Vet Comp Oncol; 2010 Jun; 8(2):138-52. PubMed ID: 20579327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicity, dosage, and efficacy of vinorelbine (Navelbine) in dogs with spontaneous neoplasia.
    Poirier VJ; Burgess KE; Adams WM; Vail DM
    J Vet Intern Med; 2004; 18(4):536-9. PubMed ID: 15320594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of neoadjuvant prednisone administration and surgical excision in treatment of cutaneous mast cell tumors in dogs.
    Stanclift RM; Gilson SD
    J Am Vet Med Assoc; 2008 Jan; 232(1):53-62. PubMed ID: 18167109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trial of vinblastine in dogs with transitional cell carcinoma of the urinary bladder.
    Arnold EJ; Childress MO; Fourez LM; Tan KM; Stewart JC; Bonney PL; Knapp DW
    J Vet Intern Med; 2011; 25(6):1385-90. PubMed ID: 22092632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter prospective trial of hypofractionated radiation treatment, toceranib, and prednisone for measurable canine mast cell tumors.
    Carlsten KS; London CA; Haney S; Burnett R; Avery AC; Thamm DH
    J Vet Intern Med; 2012; 26(1):135-41. PubMed ID: 22176473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphorylated KIT as a predictor of outcome in canine mast cell tumours treated with toceranib phosphate or vinblastine.
    Thamm DH; Weishaar KM; Charles JB; Ehrhart EJ
    Vet Comp Oncol; 2020 Jun; 18(2):169-175. PubMed ID: 31365175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy: a Southwest Oncology Group study.
    Whitehead RP; Moon J; McCachren SS; Hersh EM; Samlowski WE; Beck JT; Tchekmedyian NS; Sondak VK;
    Cancer; 2004 Apr; 100(8):1699-704. PubMed ID: 15073859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vinorelbine rescue therapy for dogs with primary urinary bladder carcinoma.
    Kaye ME; Thamm DH; Weishaar K; Lawrence JA
    Vet Comp Oncol; 2015 Dec; 13(4):443-51. PubMed ID: 23981116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective study of radiation therapy for the treatment of grade 2 mast cell tumors in 32 dogs.
    al-Sarraf R; Mauldin GN; Patnaik AK; Meleo KA
    J Vet Intern Med; 1996; 10(6):376-8. PubMed ID: 8947870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The tyrosine kinase inhibitor imatinib [STI571] induces regression of xenografted canine mast cell tumors in SCID mice.
    Kobie K; Kawabata M; Hioki K; Tanaka A; Matsuda H; Mori T; Maruo K
    Res Vet Sci; 2007 Apr; 82(2):239-41. PubMed ID: 16919303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
    Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE
    Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologic behavior and prognostic factors for mast cell tumors of the canine muzzle: 24 cases (1990-2001).
    Gieger TL; Théon AP; Werner JA; McEntee MC; Rassnick KM; DeCock HE
    J Vet Intern Med; 2003; 17(5):687-92. PubMed ID: 14529136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.
    London CA; Malpas PB; Wood-Follis SL; Boucher JF; Rusk AW; Rosenberg MP; Henry CJ; Mitchener KL; Klein MK; Hintermeister JG; Bergman PJ; Couto GC; Mauldin GN; Michels GM
    Clin Cancer Res; 2009 Jun; 15(11):3856-65. PubMed ID: 19470739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.